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Abstract
Background: Recent studies in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis
(MS), suggest an involvement of the histone methyltransferase enhancer of zeste 2 polycomb repressive complex 2
subunit (EZH2) in important processes such as cell adhesion and migration.
Methods: Here, we aimed to expand these initial observations by investigating the role of EZH2 in MS. mRNA expression
levels for EZH2 were measured by real-time PCR in peripheral blood mononuclear cells (PBMC) from 121 MS
patients (62 untreated and 59 receiving treatment) and 24 healthy controls.
Results: EZH2 expression levels were decreased in PBMC from untreated patients compared to that from controls, and
treatment significantly upregulated EZH2 expression. Expression of miR-124 was increased in MS patients compared to
controls. Blood immunophenotyping revealed EZH2 expression mostly restricted to CD4+ and CD8+ T cells, and
circulating EZH2+ CD4+ and CD8+ T cells were decreased in untreated MS patients compared to controls. CD8+
T cells expressing EZH2 exhibited a predominant central memory phenotype, whereas EZH2+ CD4+ T cells were
of effector memory nature, and both T cell subsets produced TNF-α. EZH2+ T cells were enriched in the cerebrospinal
fluid compartment compared to blood and were found in chronic active lesions from MS patients. EZH2 inhibition and
microarray analysis in PBMC was associated with significant downregulation of key T cell adhesion molecules.
Conclusion: These findings suggest a role of EZH2 in the migration of T cells in MS patients. The observation of TNF-α
expression by CD4+ and CD8+ T cells expressing EZH2 warrants additional studies to explore more in depth
the pathogenic potential of EZH2+-positive cells in MS.
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Background
Enhancer of zeste 2 polycomb repressive complex 2 sub-
unit (EZH2) is a histone methyltransferase that serves as
the catalytic subunit of the polycomb repressive complex
2, a protein complex that regulates gene expression by
methylating nucleosomal histone H3 at lysine 27 (H3K27)
on the promoter of its target genes [1]. The identification
of a cytosolic methyltransferase EZH2-containing complex
suggested that, in addition to its role methylating his-
tones, EZH2 could also be involved in the regulation of
extra-nuclear signaling pathways, in particular actin
polymerization-dependent processes [2]. Recent investi-
gation on its cytoplasmic role has revealed that EZH2
interacts with cytosolic proteins such as talin and the
guanine nucleotide–exchange factor vav1 that link in-
tegrin molecules to the actin cytoskeleton, suggesting
the potential implication of EZH2 in cell adhesion and
migration processes [3]. Interestingly, mice lacking the
EZH2 gene exhibited attenuated experimental auto-
immune encephalomyelitis (EAE) disease progression
due to the inability of EZH2-deficient cells, particularly
neutrophils and dendritic cells, to reach the site of in-
flammation [3]. Taking into consideration the findings
of EZH2 in EAE mice and its implication in important
processes for the pathogenesis of multiple sclerosis
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such as cell adhesion and migration, we believe that
EZH2 may also be playing a role in multiple sclerosis
and contribute to the inflammatory component observed
in the central nervous system (CNS) of patients. Hence,
the purpose of the present study was to explore the role of
EZH2 in the disease by measuring the gene expression
levels of EZH2 and associated molecules in peripheral
blood cells from untreated and treated multiple sclerosis
patients and by characterizing the immune cell popula-




Messenger RNA (mRNA) expression levels of EZH2, talin
1 (TLN1), and VAV1 were determined in peripheral blood
mononuclear cells (PBMC) from a first cohort of 24 healthy
controls (HC) and 62 treatment-naïve multiple scler-
osis patients. The case group included 25 patients with
relapsing-remitting multiple sclerosis (RRMS), 20 patients
with secondary progressive multiple sclerosis (SPMS), and
17 patients with primary progressive multiple sclerosis
(PPMS). The RRMS group included 20 patients in clinical
remission and 5 patients whose blood was drawn at the
time of an acute relapse.
Validation cohort
In order to replicate EZH2 findings, mRNA expression
levels for EZH2 were also measured in PBMC from an
independent validation cohort comprised of 12 HC and
13 treatment-naïve multiple sclerosis patients. Considering
that EZH2 expression levels in the initial cohort were
similar between different clinical forms of the disease,
for the validation cohort, only patients with RRMS
were included.
Treated cohort
EZH2 and TLN1 mRNA expression levels were deter-
mined in an additional cohort of 59 RRMS patients
treated for at least 1 year with interferon-beta (n =
17), glatiramer acetate (n = 15), fingolimod (n = 16), or
natalizumab (n = 11). Expression levels for these genes
were compared with those observed in a subgroup of
14 untreated RRMS patients included in the initial
cohort.
The study was approved by the local Ethics Committee
[EPA(AG)57/2013(3834)], and participants gave written
informed consent. Tables 1 and 2 summarize demo-
graphic and baseline clinical characteristics of mul-
tiple sclerosis patients from the initial, validation, and
treated cohorts and the HC included in the study.
Sample collection and determination of mRNA expression
levels of EZH2, TLN1, and VAV1 by real-time PCR
PBMC from multiple sclerosis patients and HC were iso-
lated by Ficoll-Isopaque density gradient centrifugation
(Gibco BRL, Life Technologies LTD, UK) and stored in
liquid nitrogen until used. Total RNA was extracted from
PBMC using an RNeasy kit (Quiagen, Santa Clarita, USA)
and cDNA synthesized using the High-Capacity cDNA
Archive kit (Applied Biosystems, Foster City, CA, USA).
mRNA expression levels for EZH2, TLN1, and VAV1 were
determined with TaqMan® probes specific for the gene (Ap-
plied Biosystems). The housekeeping gene glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) was used as an
endogenous control (Applied Biosystems). Assays were run
on the ABI PRISM® 7900HT system (Applied Biosystems),
and data were analyzed with the 2−ΔΔCT method [4].
Determination of microRNA expression levels by real-time
PCR
Expression levels for miR-124 and miR-155 were deter-
mined according to sample availability in PBMC from a
subgroup of 18 HC and 21 untreated multiple sclerosis
patients (15 RRMS and 6 SPMS patients) who were also
included in the initial cohort. Additional file 1: Table S1
summarizes demographic and main clinical characteristics
of individuals included for this part of the study. PBMC
were collected and processed in the same conditions as
described in the previous section. Expression levels
for miR-124 and miR-155 were measured with Taq
Man® probes specific for the microRNAs (Applied
Biosystems) using RNU 6b as endogenous control.
Analysis was performed as described above with the
2−ΔΔCT method [4].
EZH2 immunophenotyping
EZH2 protein expression was determined by flow cytome-
try according to sample availability in PBMC from 13 HC
[9 females (69.2%); mean age (standard deviation), 35.8 years
(10.9)] and 10 RRMS patients [5 females (50%); mean age,
32.1 years (13.5); mean disease duration, 4.5 (3.5)] at base-
line and after 1 year of natalizumab treatment. Only one
MS patient and one HC were also included in the initial
cohort whereas the remaining individuals corresponded to
new multiple sclerosis patients and HC. EZH2 expression
was also determined in cerebrospinal fluid (CSF) cells from
3 untreated RRMS patients [2 females (66.7%); mean age,
34.3 years (11.9); mean disease duration, 0.4 (0.5)]. CSF
samples were collected by lumbar puncture for clinical
purposes and centrifuged at 1200g for 15 min. Superna-
tants were stored at − 80 °C until processed for clinical
tests and CSF cells resuspended in PBS and labeled as
described below.
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Monoclonal antibodies
The following monoclonal antibodies were used in the
study: EZH2-Alexa Fluor 488, CD197-PE (CCR7-PE),
CD3-PE, granulocyte/macrophage colony-stimulating
factor (GM-CSF)-PE, CD16-PE-Cy5, tumor necrosis fac-
tor (TNF)-α-PercP-Cy5.5, CD19-PE-Cy7, CD45RO-APC,
CD56-APC, CD8-APC-H7, CD14-APC-H7, CD3-BV421,
CD45-V450, CD45-V500 (all from BD Biosciences, San
Diego, CA), and IL-17-APC (R&D Systems, Minneapolis,
MN).
Characterization of EZH2 expression by CSF cells
CSF cells were stained for 30 min at 4 °C in the dark
with the appropriate amounts of monoclonal antibodies
recognizing the surface antigens. Subsequently, cells
were washed with PBS, fixed and permeabilized for
20 min at 4 °C in the dark with Cytofix/Cytoperm Kit
(BD Biosciences), washed twice with Perm/Wash solution
(BD Biosciences) and stained intracellularly for 30 min at
4 °C in the dark with a monoclonal antibody recognizing
EZH2, and washed and analyzed in a FACSCanto II flow
cytometer (BD Biosciences).
Intracellular cytokine staining
Aliquots of 106 PBMC were resuspended in 1 ml of
complete medium with 50 ng/ml phorbol 12-myristate
13-acetate (PMA) (Sigma-Aldrich, St. Louis, MO) and
750 ng/ml ionomycin (Sigma-Aldrich), in the presence
of 2 μg/ml brefeldin A (GolgiPlug, BD Biosciences) and
2.1 μM monensin (Golgi Stop, BD Biosciences) in poly-
propylene tubes, and incubated for 4 h at 37 °C in 5%
CO2. Cells were washed in PBS and surface stained as
indicated above. Afterward, cells were fixed and perme-
abilized for 20 min at 4 °C in the dark with Cytofix/
Cytoperm Kit (BD Biosciences), washed twice with
Perm/Wash solution (BD Biosciences), and stained with
Table 2 Summary of demographic and baseline clinical characteristics of the treated MS cohort
Characteristics UNT IFN GA FG NTZ
N 14 17 15 16 11
Age (years) 28.3 (6.3) 34.8 (7.5) 32.3 (7.9) 30.3 (7.8) 27.7 (14.5)
Female/male (% women) 8/6 (57.2) 9/8 (52.9) 8/7 (53.3) 11/5 (68.7) 7/4 (63.6)
Duration of disease (years) 3.3 (2.7) 5.0 (10.7) 6.7 (5.8) 3.0 (3.8) 6.1 (7.0)
EDSSa 1.8 (1.4–2.5) 1.6 (1.0–2.0) 2.2 (1.5–3.0) 1.6 (1.0–2.0) 2.5 (1.6–3.5)
Numbers of relapsesb 2.0 (0.8) 1.5 (0.8) 2.3 (1.5) 2.2 (0.7) 1.9 (0.6)
Data are expressed as mean (standard deviation) unless otherwise stated
UNT untreated relapsing-remitting MS patients, IFN interferon-beta, GA glatiramer acetate, FG fingolimod, NTZ natalizumab
aData are expressed as mean (interquartile range) and refers to EDSS at the time of treatment onset
bThe number of relapses in the 2 years before treatment onset
Table 1 Demographic and baseline clinical characteristics of the MS patients and healthy controls
Baseline characteristics HC RRMS SPMS PPMS Relapse
Initial cohort
N 24 20 20 17 5
Age (years) 30.2 (7.2) 30.0 (7.8) 45.7 (8.7) 50.2 (7.3) 30.8 (8.7)
Female/male (% women) 18/6 (75.0) 10/10 (50.0) 11/9 (55.0) 11/6 (64.7) 2/3 (40.0)
Duration of disease (years) – 4.8 (4.6) 11.5 (7.6) 12.2 (7.9) 2.2 (2.7)
EDSSa – 1.7 (1.0–4.2) 4.0 (3.5–5.1) 6.0 (4.0–6.0) 3.0 (2.5–5.3)
Numbers of relapsesb – 2.2 (0.7) 0.8 (0.8) – 2.6 (1.3)
Validation cohort
N 12 13
Age (years) 28.2 (6.0) 37.6 (9.3)
Female/male (% women) 8/3 (72.7) 12/2 (85.7)
Duration of disease (years) – 3.8 (3.2)
EDSSa – 2.5 (1.0–3.5)
Numbers of relapsesb – 2.5 (0.8)
Data are expressed as mean (standard deviation) unless otherwise stated
RRMS relapsing-remitting multiple sclerosis, SPMS secondary progressive multiple sclerosis, PPMS primary progressive multiple sclerosis, Relapse RRMS patients
whose blood was collected at the time of an acute exacerbation
aData are expressed as mean (interquartile range)
bThe number of relapses in the 2 years before blood collection
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monoclonal antibodies recognizing GM-CSF, TNF-α,
and IL-17.
Flow cytometry analysis
Cells were always analyzed within 1 h of staining. Mean
autofluorescence values were set using appropriate nega-
tive isotype controls. Data analysis was performed using
FACSDiva Software V.8.0 (BD Biosciences). A gate includ-
ing lymphocytes and monocytes and excluding debris and
apoptotic cells was established; a minimum amount of
30,000 events for PBMC samples and 500 events for CSF
cells were analyzed.
EZH2 expression in EAE mice
Anesthetized C57BL/6 mice were immunized by subcuta-
neous injections of PBS containing 50 μg of MOG35–55
(Proteomics Section, Universitat Pompeu Fabra, Barcelona,
Spain) or PBS, emulsified in complete Freund’s adjuvant
(Sigma Chemical, St. Louis, MO, USA), and supplemented
with 2 mg/ml Mycobacterium tuberculosis H37RA (Difco
Laboratories, Detroit, MI, USA). The animals received an
additional intravenous injection of 150 ng pertussis toxin in
100 μl PBS on the day of immunization and again 48 h
later. Four animals per group (EAE or controls—
PBS) were sacrificed at 8, 16, 22, 29, 36, and 50 days
post-immunization, and spinal cord tissue was subse-
quently obtained. mRNA expression levels of EZH2
and CD3e were determined by real-time PCR as previously
described. Changes in gene expression were always com-
pared with animals treated with PBS at the respective days.
EZH2 expression in human brain tissue
Samples
Paraffin-embedded brain samples from RRMS patients
and non-neurological controls were provided by the UK
Multiple Sclerosis Tissue Bank. Tissue sections were stained
with hematoxylin and eosin (HE) and Klüver-Barrera (KB)
for inflammation and demyelination assessment. Ten sam-
ples from multiple sclerosis patients with chronic active
lesions and four control samples were selected for the study
(demographic and clinical information was not available for
these patients).
Immunohistochemistries
Immunostainings were developed with the automated
Benchmark XT platform from Ventana Medical System.
Briefly, 4-μm-thick, paraffin-embedded serial sections
were deparaffinized with EZ prepTM (Ventana Medical
System). Antigen retrieval was performed with Cell Con-
ditioning 1 pH= 8 (Ventana Medical System) for 30 min.
Endogenous peroxidase activity was blocked with hydro-
gen peroxide 3%. Samples were incubated with rabbit
anti-EZH2 (clone EPR9307(2), Abcam) for 36 min and vi-
sualized with ultraView Universal DAB (Ventana Medical
Systems). Subsequently, samples were kept at 95 °C for
8 min and incubated with rabbit anti-CD4 (clone SP35,
Ventana Medical System) or rabbit anti-CD8 (clone SP57,
Ventana Medical System) for 40 min and visualized with
ultraView Universal Alkaline Phosphatase Red Detection
(Ventana Medical Systems). All samples were counter-
stained with hematoxylin.
Immunostaining assessment
A range between 5 and 20 pictures were taken for each
multiple sclerosis sample. Total CD4+ and CD8+ T cells
and double-positive EZH2 and CD4 or CD8 cells were
counted. The percentages of double-positive cells were cal-
culated with respect to the total of CD4+ or CD8+ Tcells.
EZH2 blocking and gene expression microarrays
PBMC from 7 untreated RRMS patients [5 females (71.4%);
mean age, 39.0 years (8.0); mean disease duration, 7.0 years
(5.1)] were plated into 24-well plates for 24 h in the pres-
ence or absence of an EZH2 inhibitor (histone deacetylase
inhibitor suberoylanilide hydroxamic acid—SAHA) at 1 μg/
μl concentration. After 24 h, cells were harvested and total
RNA isolated using the RNeasy kit (Quiagen) and hybrid-
ized to Affymetrix Human Transcriptome Arrays (HTA
2.0) (Affymetrix, Santa Clara, CA, USA) according to the
manufacturer’s protocol (GeneChip WT Pico Reagent Kit
(Affymetrix)).
Statistical analysis
Statistical analysis was performed by using the SPSS 17.0
package (SPSS Inc., Chicago, IL) for MS Windows. Com-
parisons of mRNA expression levels for EZH2, TLN1,
and VAV1; expression levels for miR-124 and miR-155;
and the percentage of EZH2-positive cells between the
different study groups were performed by parametric
and non-parametric tests depending on the applicability
conditions. Real-time PCR data were expressed as fold
change in gene expression in controls relative to the
whole group of multiple sclerosis patients and patients
stratified according to the different clinical forms, in RRMS
patients in clinical remission relative to patients in relapse,
and in treated RRMS relative to untreated patients. For
microarray analysis, images were processed with AGCC,
Affymetrix GeneChip Command Console, to generate .CEL
files. Raw expression values obtained directly from .CEL
files were pre-processed using the RMA method [5]. These
normalized values were the basis for all the subsequent ana-
lyses. Previous to any analysis data were submitted to
non-specific filtering to remove low-signal genes (those
genes whose mean signal in each group did not exceed a
minimum threshold) and low-variability genes (those genes
whose standard deviation between all samples did not ex-
ceed a minimum threshold). The selection of differentially
expressed genes between the untreated and the EZH2
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blocking conditions was based on a linear model analysis
with empirical Bayes moderation of the variance estimates
following the methodology developed by Smyth [6]. In
order to deal with the multiple testing issues derived from
the fact that many tests (one per gene) were performed
simultaneously, p values were adjusted to obtain strong
control over the false discovery rate using the Benjamini
and Hochberg method [7].
Results
EZH2 expression is decreased in multiple sclerosis patients
In order to investigate the role of EZH2 in multiple
sclerosis, we first measured the mRNA expression levels
of EZH2 and EZH2-associated genes in PBMC from an
initial cohort of 62 untreated multiple sclerosis patients
and 24 HC. As shown in Fig. 1a, expression levels for
EZH2, TLN1, and VAV1 were significantly decreased in
PBMC from the whole multiple sclerosis group com-
pared to controls. Further stratification of the multiple
sclerosis group into the different clinical forms revealed
significantly decreased gene expression levels of EZH2,
TLN1, and VAV1 in PBMC from RRMS, SPMS, and
PPMS patients compared to HC (Fig. 1b). As depicted in
Fig. 1c, mRNA expression levels for EZH2, TLN1, and
VAV1 were not changed in RRMS patients at the time of
acute exacerbations, and expression levels for these
genes were similar between RRMS patients in clinical re-
mission and RRMS patients during relapse.
EZH2 findings were validated in an independent cohort
of 13 untreated multiple sclerosis patients and 12 HC, and
mRNA expression levels for EZH2 were again found to be
significantly decreased in PBMC from the multiple scler-
osis group compared to the HC group (p = 0.01; Fig. 1d).
Expression levels of miR-124 are increased in multiple
sclerosis patients
We next investigated the expression levels of miR-124 and
miR-155, two microRNAs that are known on the one
hand to target EZH2 [8, 9] and on the other hand to be in-
volved in multiple sclerosis [10, 11]. Following the deter-
mination of microRNA expression levels in 21 untreated
multiple sclerosis patients and 18 HC, miR-124 expression
was found to be significantly upregulated in PBMC from
multiple sclerosis patients compared to controls (p = 0.03),
whereas miR-155 expression levels were similar between
patients and HC (Fig. 2). These results may suggest a
potential and inverse relationship between EZH2 and
miR-124 expression levels in multiple sclerosis patients.
EZH2 expression is increased in treated multiple sclerosis
patients
As a next step, we investigated whether EZH2 and TLN1
expression was modulated by commonly used multiple
sclerosis therapies. For this, mRNA expression levels for
EZH2 and TLN1 were determined in PBMC from 59
treated patients. Compared to untreated patients, EZH2
and TLN1 expression was significantly upregulated in
PBMC by the effect of interferon-beta, Copaxone, and nata-
lizumab treatments (Fig. 3). In contrast, whereas fingolimod
significantly increased TLN1 expression, this treatment had
no effect on EZH2 expression (Fig. 3). Overall, the in-
creased EZH2 and TLN1 expression in PBMC from treated
MS patients may indicate a reduced leukocyte trafficking
into the CNS by the effect of treatment.
EZH2 is expressed by circulating CD4+ and CD8+ T cells
with effector memory and central memory phenotypes
respectively
In order to characterize the PBMC populations that
express EZH2, immunophenotyping for EZH2 and flow
cytometry analysis was performed in T cells (CD3+,
CD4+, and CD8+), B cells, monocytes, and NK cells
from 10 multiple sclerosis patients and 13 HC. EZH2
expression was restricted to CD3+ (both CD4+ and
CD8+) T cells and CD56dim NK cells (Fig. 4a), whereas
it was absent in B cells and monocytes. Similar to the
mRNA expression findings observed in the whole
PBMC population, the percentage of EZH2-positive
cells in CD4+ and CD8+ T cells was significantly re-
duced in untreated multiple sclerosis patients com-
pared to controls (Fig. 4a). Although treatment with
natalizumab, which was selected as control therapy, in-
creased EZH2 expression by T cells, differences did not
reach statistical significance (Fig. 4a). In contrast, EZH2
expression by CD56dim NK cells was similar across the
different groups (Fig. 4a).
Further, EZH2 immunophenotyping in naïve and differ-
ent memory T cell populations revealed that CD4+ T cells
expressing EZH2 had a clear effector memory phenotype
with low contribution of naïve T cells compared to CD4+
T cells negative for EZH2 expression (Fig. 4b). In contrast,
CD8+ T cells expressing EZH2 exhibited a predominant
central memory phenotype compared to EZH2-negative
CD8+ T cells (Fig. 4c). A trend towards decreased expres-
sion of EZH2 (p = 0.07) was observed in terminally differ-
entiated effector CD4+ T cells from untreated multiple
sclerosis patients compared to HC, and EZH2 expression
was significantly upregulated in patients by the effect of
natalizumab treatment (p = 0.03) (Fig. 4b). However, a
similar pattern was also observed in terminally differenti-
ated effector CD4+ T cells negative for EZH2 (p = 0.05
and p = 0.003 in untreated patients versus controls and
patients receiving treatment respectively) (Fig. 4b).
Finally, in order to evaluate the pathogenic potential of
EZH2-positive cells, staining for proinflammatory cyto-
kines such as TNF-α, GM-CSF, and IL-17 was also in-
cluded in CD4+ and CD8+ T cells from a subgroup of
untreated (N = 4) and treated (N = 4) patients and HC
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(N = 7). EZH2-positive cells expressed TNF-α though were
negative for GM-CSF and IL-17 expression. Interestingly,
trends towards decreased percentage of TNF-α-positive
cells were observed in CD4+ and CD8+ T cells expressing
EZH2 from untreated patients compared to HC (p = 0.08
and p = 0.07 respectively), whereas no similar findings were
seen in their EZH2-negative counterparts (Fig. 4d). Further-
more, natalizumab treatment was associated with signifi-
cant increases in the percentage of TNF-α-positive cells in
CD4+ and CD8+ T cells expressing EZH2 (p = 0.02 and
p = 0.04 respectively), while treatment had no effect in
the percentage of TNF-α-positive cells by EZH2-negative
CD4+ and CD8+ T cells (Fig. 4d).
Altogether, these data point to a different expression
of EZH2 depending on the differentiation stages of the
CD4+ and CD8+ T cells and suggest a common patho-
genic potential of EZH2-positive cells in MS via TNF-α
production.
Fig. 1 Expression levels of EZH2 and EZH2-associated molecules in multiple sclerosis patients and controls. mRNA expression levels for EZH2,
TLN1, and VAV1 were determined in PBMC from untreated multiple sclerosis patients and healthy controls by real-time PCR relative quantification, as
described in the “Methods” section. Graphs showing expression levels for EZH2, TLN1, and VAV1 a–c in the initial discovery cohort and d in an
independent cohort of patients and controls. Results are expressed as fold change (standard error of the mean) in gene expression in multiple
sclerosis patients relative to controls and in patients in relapse relative to patients in remission. Statistics: unpaired Student’s t test. *p values < 0.05; **p
values < 0.01; ***p values < 0.001. HC healthy controls, MS whole group of multiple sclerosis patients, RRMS relapsing-remitting multiple sclerosis, SPMS
secondary progressive multiple sclerosis, PPMS primary progressive multiple sclerosis, Remission RRMS patients in clinical remission, Relapse RRMS
patients whose blood was collected at the time of an acute exacerbation, EZH2 enhancer of zeste 2 polycomb repressive complex 2 subunit, TLN1
talin 1, VAV1 vav guanine nucleotide exchange factor 1
Malhotra et al. Journal of Neuroinflammation          (2018) 15:296 Page 6 of 12
EZH2-positive T cells migrate to the CNS during EAE and
multiple sclerosis
Based on the gene and protein expression findings, we hy-
pothesized that the decrease of circulating EZH2-positive
T cells in untreated multiple patients compared to con-
trols was secondary to the migration of EZH2-positive T
cells into the CNS. To evaluate this hypothesis, we first in-
vestigated EZH2 expression in the CNS of EAE mice and
observed that EZH2 was expressed in spinal cord tissue
during EAE, and EZH2 expression levels peaked at the
inflammatory phase of the disease (day 16 post-
immunization) (Fig. 5a). Interestingly, EZH2 followed
a similar temporal pattern of CNS expression to Cd3
in EAE mice, and expression levels for these two genes cor-
related with each other (Spearman correlation coefficient =
0.63, p = 0.002), suggesting a relationship between EZH2
expression and the inflammatory cell infiltrate during EAE
(Fig. 5a). We next aimed to extrapolate these findings to
patients with multiple sclerosis by determining EZH2
expression in CSF cells from three untreated patients. As
shown in Fig. 5b, EZH2-positive T cells were enriched in
the CSF compartment, and the percentage of CD3+ T cells
expressing EZH2 was significantly increased in the CSF
compared to peripheral blood (p = 0.007). In contrast, in
CD56dim NK cells, a cell subset that also expressed EZH2
(Fig. 4a), the percentage of EZH2-positive cells did not dif-
fer between the CSF and blood compartments, indicating a
preferential capacity for EZH2-positive T cells to migrate
into the CNS. In this line, we finally investigated EZH2 ex-
pression in chronic active lesions from 10 multiple sclerosis
Fig. 2 Expression levels of miR-124 and miR-155 in multiple sclerosis patients and controls. Expression levels for miR-124 and miR-155 were
determined in PBMC from untreated multiple sclerosis patients and controls by real-time PCR relative quantification. Results are expressed as fold
change (standard error of the mean) in gene expression in patients relative to controls. Statistics: unpaired Student’s t test. *p value = 0.03. HC
healthy controls, MS whole group of untreated multiple sclerosis patients, which included 15 RRMS and 6 SPMS patients
Fig. 3 Expression levels of EZH2 and TLN1 in treated multiple sclerosis patients. mRNA expression levels for EZH2 and TLN1 were determined by
real-time PCR relative quantification in PBMC from untreated multiple sclerosis patients and patients receiving disease-modifying therapies for at
least 1 year. Results are expressed as fold change (standard error of the mean) in gene expression in patients relative to controls. Statistics: Mann-
Whitney U test. *p values < 0.001. UNT untreated patients, IFN interferon-beta, GA glatiramer acetate, FG fingolimod, NTZ natalizumab, EZH2
enhancer of zeste 2 polycomb repressive complex 2 subunit, TLN1 talin 1
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patients and observed that 8.5% (mean percentage) and
10.9% of the total CD4+ and CD8+ T cells were expressing
EZH2 respectively (Fig. 5c). Occasionally, EZH2 expression
was also observed in the nuclei of few glial cells, and brain
tissues from non-neurological controls were negative for
EZH2 expression (data not shown).
EZH2 blocking downregulates T cell adhesion molecules
As a last step, we incubated in vitro PBMC from seven
untreated multiple sclerosis patients with an EZH2
inhibitor in order to investigate the genes modulated by
EZH2 and aiming to better understand the role of EZH2
in disease pathophysiology. A total of 6763 genes were
significantly up- or downregulated by the effect of the
EZH2 inhibitor (with p values < 0.05; data not shown).
Interestingly, among the top 1% of differentially expressed
genes between the untreated and treated conditions, we
identified key T cell adhesion molecules that were strikingly
downregulated by the EZH2 inhibitor such as selectin L
(SELL, also known as CD62L; adjusted p value versus the
Fig. 4 EZH2 immunophenotyping in PBMC from multiple sclerosis patients and controls. a Graphs showing the percentage of EZH2-positive cells
in T cells and CD56dim NK cells from healthy controls (HC; n = 13), untreated multiple sclerosis patients (UNT; n = 10), and the same cohort of
patients after 1 year of natalizumab treatment (NTZ; n = 10). b, c Graphs showing EZH2 expression in different CD4+ and CD8+ T cell subsets (HC,
n = 13; UNT, n = 10; NTZ, n = 10). Naïve T cells were defined as CD45RO−/CCR7+. Central memory (CM) T cells were defined as CD45RO+/CCR7+.
Effector memory (EM) T cells were defined as CD45RO+/CCR7−. Terminally differentiated (TD) effector T cells were defined as CD45RO−/CCR7+.
Gray boxes, EZH2-positive cells; open boxes, EZH2-negative cells. d Graphs showing the percentage of tumor necrosis factor (TNF)-α-positive cells
in CD4+ and CD8+ T cells expressing EZH2 (HC, n = 7; UNT, n = 4; NTZ, n = 4). Gray boxes, EZH2-positive cells; open boxes, EZH2-negative cells.
Statistics: a, b unpaired Student’s t test; c, d Mann-Whitney U test. *p values < 0.05; **p values < 0.01; ***p values < 0.001. EZH2 enhancer of zeste
2 polycomb repressive complex 2 subunit
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untreated condition = 6.4 × 10−20), integrin subunit alpha 4
(ITGA4, also known as CD49D; p = 3.6 × 10−16), integrin
subunit alpha L (ITGAL, also known as CD11A; p = 1.1 ×
10−13), and platelet and endothelial cell adhesion molecule
1 (PECAM1; p = 5.2 × 10−14) (Fig. 6). These data support a
role of EZH2 in the adhesion of circulating T cells.
Discussion
Extensive literature exists about the role of EZH2 as histone
methyltransferase and, particularly, about EZH2 involve-
ment in a wide range of malignant tumors [8, 12, 13] due
to its function as epigenetic silencer [14]. The identification
of a cytosolic methyltransferase complex containing EZH2
suggested that, in addition to its nuclear role, EZH2 could
also be involved in other important cellular processes
such as cell adhesion and migration [2]. In an attempt
to characterize more in depth the cytosolic role of
EZH2, Gunawan et al. [2] recently reported that EZH2
was critical for regulating leukocyte migration to sites
of inflammation in EAE mice, findings that opened a
potential and attractive link between EZH2 and auto-
immune disorders such as multiple sclerosis in which
cell adhesion and migration are critical pathogenic
mechanisms [15]. Despite this initial publication in the
animal model of multiple sclerosis [3], to date, there
are no studies of EZH2 in patients with multiple scler-
osis. Aiming to explore the role of EZH2 in multiple
sclerosis, we first determined mRNA expression levels
in PBMC from untreated patients and healthy individ-
uals and observed that EZH2, together with molecules
reported to be associated with cytosolic EZH2 such as
TLN1 and VAV1 [3], were all downregulated in mul-
tiple sclerosis patients regardless of whether they were
having relapse-onset or progressive clinical forms, or
whether they were in clinical remission or in acute re-
lapse. The decreased expression of EZH2 in PBMC
from patients with multiple sclerosis was replicated in
an independent validation cohort of patients and con-
trols. These initial observations at the gene expression
level suggested an involvement of EZH2 in the disease,
which was explored in additional experiments.
We first explored microRNAs, which are known to
exert regulatory functions at the posttranscriptional level
via binding to the 3′ untranslated region of target mRNAs
Fig. 5 EZH2 expression in the CNS of EAE and multiple sclerosis patients. a Graphs showing expression levels for EZH2 and Cd3 in spinal cord
from EAE mice (black bars) and control mice (open bars). The x-axis indicates days post-immunization (d) and number of EAE and control mice
per group. b Boxplots showing the percentage of CD3+ T cells and CD56dim NK cells expressing EZH2 in the CSF and peripheral blood compartments of
multiple sclerosis patients (n= 3 for CSF; n= 10 for blood). c Expression of EZH2 in CD4+ and CD8+ T cells from chronic active lesions of multiple sclerosis
patients (N= 10). Arrows indicate CD4+ or CD8+ T cells expressing EZH2. Graph shows the percentage of CD4+ and CD8+ T cells expressing EZH2 in CNS
lesions. Bars represent mean (standard error of the mean). Statistics: a unpaired Student’s t test; b Mann-Whitney U test. *p values < 0.05; **p values < 0.01;
***p values < 0.001. EZH2, enhancer of zeste 2 polycomb repressive complex 2 subunit; Cd3 Cd3e, CD3 antigen, epsilon polypeptide
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[16]. In the search for potential microRNAs that on the
one hand regulated EZH2 expression and on the other
hand were involved in multiple sclerosis, the microRNAs
miR-124 and miR-155 emerged as attractive candidates
[8, 9]. In this context, expression levels for miR-124
were found increased in demyelinated hippocampi from
postmortem brains of multiple sclerosis patients [10].
miR-155 expression was upregulated in peripheral blood
monocytes and active lesions from patients [11]. In our
study, when expression levels for these two microRNAs
were determined in PBMC from a subgroup of untreated
multiple sclerosis patients and controls, miR-124 but not
miR-155 was significantly upregulated in patients, suggest-
ing a potential functional relationship between decreased
EZH2 mRNA expression levels and miR-124 upregulation
in patients with multiple sclerosis. These findings warrant
future studies to investigate the cell types that contribute
to miR-124 upregulation.
In order to explore whether the expression of EZH2
and associated molecules was modulated by commonly
used disease-modifying therapies in patients with multiple
sclerosis, a cohort of patients treated with interferon-beta,
glatiramer acetate, fingolimod, and natalizumab was also in-
cluded in the study. Treatment with interferon-beta, glatira-
mer acetate, and natalizumab was associated with increased
expression levels of EZH2 and TLN1. By contrast, fingoli-
mod treatment was only associated with upregulated ex-
pression of TLN1. Although based on a small number of
samples and in spite of the descriptive nature of the experi-
ments, it is tempting to speculate that this finding may be
due to the different mechanisms by which these drugs
regulate leukocyte migration to the CNS, being the mech-
anism of action of fingolimod not exerted in peripheral
blood but in the lymph nodes where it retains naïve and
central memory lymphocytes [17–20]. In view of these data,
we hypothesize that the reduction in EZH2 expression ob-
served in untreated patients with subsequent upregulation
after treatment may indicate a migration capacity of PBMC
expressing EZH2 to the CNS that is inhibited by the effect
of treatment. These findings also open a new research
Fig. 6 Expression of cell adhesion molecules in PBMC following EZH2 blocking. Boxplots showing expression levels obtained with microarrays for
adhesion molecules before and after incubation of PBMC from multiple sclerosis patients with an EZH2 inhibitor for 24 h. The asterisk symbol
refers to adjusted p values < 0.001. UNT untreated condition, SELL selectin L, ITGA4 integrin subunit alpha 4, ITGAL integrin subunit alpha L,
PECAM1 platelet and endothelial cell adhesion molecule 1
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avenue to investigate whether the increase in EZH2
expression observed after treatment is associated with
the response to therapies and hence may differ between
responders and non-responders to each particular thera-
peutic strategy.
Immunophenotyping of the major PBMC populations
revealed restricted EZH2 expression in CD4+ and CD8+
T cells as well as CD56dim NK cells. Similar to the gene
expression findings, the percentage of EZH2-positive T
cells was reduced in untreated multiple sclerosis patients
compared to controls, pointing to a role of EZH2 in this
particular cell subset rather than in CD56dim NK cells,
which showed similar percentages of EZH2-positive cells
in patients and controls. It is worth highlighting that ex-
cept for one patient and one control, the immunopheno-
typing cohort included new individuals, and hence, the
decrease of EZH2-positive T cells observed in patients
can also be considered as a new validation of the EZH2
expression findings at the protein level. Natalizumab,
which was selected as control therapy because of its
known effects reducing T cell trafficking into the CNS,
increased the percentage of EZH2-positive T cells, but,
contrary to gene expression results, differences did not
reach statistical significance. Interestingly, further T cell
immunophenotyping showed heterogeneity in the T cell
subsets positive for EZH2 expression. In this context,
most CD4+ T cells expressing EZH2 were effector mem-
ory T cells, a population that per se has the capacity to
migrate to non-lymphoid tissues including the CNS [21].
In contrast, CD8+ T cells positive for EZH2 had a pre-
dominant central memory phenotype, suggesting that
this particular subset can migrate to the CNS in MS and
may later differentiate into effector memory populations
in the sites of inflammation. Of note, EZH2-positive cells
both in CD4+ and CD8+ T cells may have pathogenic po-
tential through the secretion of TNF-α, a pro-inflammatory
cytokine involved in the pathogenesis of multiple sclerosis
[22]. Although caution should be taken when considering
these data owing to the small sample size and high variabil-
ity, these findings altogether warrant additional studies to
deepen into the pathogenic capacity of T cells expressing
EZH2 and explore whether EZH2 may become a thera-
peutic target in MS patients to reduce disease activity.
The potential for EZH2-positive T cells to migrate to the
CNS was first suggested in the EAE study, which showed
EZH2 expression in spinal cord tissue from EAE mice fol-
lowing a similar pattern to Cd3 expression over time.
Confirmation of the migratory capacity of EZH2-positive
T cells was provided by their detection in the CSF and
brain lesions from multiple sclerosis patients. Noteworthy,
the enrichment for CD4+ and CD8+ T cells expressing
EZH2 in the CSF and chronic active lesions compared to
the blood compartment suggested that the decrease of
EZH2-positive T cells observed in untreated multiple
sclerosis patients compared to healthy individuals was
secondary to their migration into the CNS. This notion
was further supported by the observation that other
EZH2-expressing blood cell populations such as CD56dim
NK cells, which did not depict differences between patients
and controls in blood, were not enriched in the CSF. Al-
though EZH2 expression in brain lesions from multiple
sclerosis patients seemed restricted to CD4+ and CD8+ T
cells, additional sources of EZH2 expression within the
CNS cannot be totally ruled out, as evidenced by EZH2
immunohistochemistry. In contrast, EZH2 expression was
not observed in brain tissue from non-neurological con-
trols, a finding that confers specificity for EZH2 expression
in the CNS of multiple sclerosis patients.
Conclusions
Finally, the implication of EZH2 in T cell adhesion, an
important step for cell migration, was supported by the
microarray findings conducted after EZH2 blocking with
a histone deacetylase inhibitor that regulates EZH2 ex-
pression [23], which showed striking downregulation of
cell adhesion molecules expressed in T cells such as SELL
[24], ITGA4 [25], ITGAL [26], and PECAM1 [27]. The
aggregate results from the study suggest a role for EZH2
in the migration of T cells into the CNS in patients with
multiple sclerosis and also suggest a potential pathogenic
capacity of EZH2-positive T cells that will need to be
explored more in depth in future studies.
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